Kalytera Therapeutics Inc (KLY.CA)
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns
SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...
Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease
Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease...
Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis
Claritas to Initiate Phase 2 Clinical Testing of R-107 in Treatment of COVID-Related Sepsis Following Completion of Phase 1 Study...
Claritas Provides Update Regarding Phase 1 Clinical Study
SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...
Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB
SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or...
Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC
SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is...
Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS
Drug is Being Tested in Patients with Acute Respiratory Distress Syndrome (“ARDS”) Caused by COVID-19
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
Claritas Announces Grant of Stock Options to Directors and Officers
Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
Study Demonstrated that Nitric Oxide Administered to Patients with Severe COVID-19 Pneumonia Significantly Improved Oxygen Levels
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
Claritas to Initiate Phase 1 Clinical Study of R-107 by August
Claritas Announces Effective Date for Share Consolidation
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
Claritas Pharmaceuticals Issues Letter to Shareholders
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Data in Animal Model of PAH Demonstrate Ability of R-107 to Durably Reverse Established Disease
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.
Company to Hold Annual and Special Meeting on June 17, 2021
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company’s Board of Directors
Dr. Enkhbaatar’s Appointment Further Expands the Company’s Expertise in Field of Nitric Oxide Therapeutics
Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
Ronald Erickson and Robin Hutchison to Resign from the Board
Claritas Announces Completion of Canine Toxicology Studies
Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107
Claritas Announces Formation of Nitric Oxide Scientific Advisory Board
Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors
Dr. Cuzzocrea’s Appointment Expands the Company’s Expertise in Field of Nitric Oxide Therapeutics
Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections
Kalytera Announces Resumption of Trading on TSXV
Company Will Change Its Name to Claritas Pharmaceuticals and Launch New Website
IIROC Trading Resumption - KLY
Kalytera Announces Change of Auditor
Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update
Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants
Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection
Exclusive License is Part of Larger Transaction to Acquire Salzman Group
Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants
Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement
